An interventional study of Golden oyster mushroom powder in Dementia and Cognitive Assessment, sponsored by National University of Singapore. Recruiting at 1 site in Singapore. Open to participants aged 45 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Dementia with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Dementia · Singapore.
Among the 25 studies in Dementia with a site in Singapore, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, and was the 25th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →7 of the 25 studies in Dementia with a site in Singapore are open now. Recruiting first, the newest first:
National Cancer Centre, Singapore · Sites in Singapore
Ages 50–99
Eli Lilly and Company · Sites in Singapore, United States, Australia and 1 more country
Ages 50–85
Duke-NUS Graduate Medical School · Sites in Singapore
Ages 21–80 · Healthy volunteers
Vincent Tay Khwee Soon · Sites in Singapore
Ages 50–80
Changi General Hospital · Sites in Singapore
Ages 21–100
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 225 across the 22 interventional studies, 400 across the 3 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.
National University of Singapore has 7 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dementia with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
| NCT07234357National Cancer Centre, SingaporeSensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Dementia with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigator's objective is to explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds.
The investigator carefully designed a randomized controlled trial (RCT) to assess the role of mushrooms in promoting cognitive functioning among around 600 middle-aged adults and young-olds.
Participants were selected based on specific inclusion criteria, such as being community-living adults aged 45-80 years with a family history of dementia or subjective cognitive decline, while consuming mushrooms no more than once a week and having no dementia, along with the exclusion of individuals with neurological or psychiatric disorders and significant sensory or motor impairments. Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: Golden oyster mushroom powder
Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance monitored using electronic diary apps. The powder contains 7.0 mg/g of ergothioneine (dry weight).
MMSE
Total scores change
Time frame: 24 months
plasma ergothioneine
Time frame: 24 months
Rey Auditory Verbal Learning Test
Time frame: 12, and 24 months
inflammatory markers
hs-CRP, TNFα, IL-1, IL-6, and etc
Time frame: 24 months
NfL
Time frame: 24 months
Epigenetic age
Time frame: 24 months
Symbol Digit Modality test
Time frame: 12, and 24 months
Clinical Dementia Rating
Time frame: 12, and 24 months
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 26 months is close to that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University of Singapore →